Can Machine Learning Predict Favorable Outcome After Radiofrequency Ablation of Hepatocellular Carcinoma?

IF 3.3 Q2 ONCOLOGY JCO Clinical Cancer Informatics Pub Date : 2024-03-01 DOI:10.1200/CCI.23.00216
Amr A Hamed, Amr Muhammed, Ebtsam A M Abdelbary, Ramy M Elsharkawy, Moustafa A Ali
{"title":"Can Machine Learning Predict Favorable Outcome After Radiofrequency Ablation of Hepatocellular Carcinoma?","authors":"Amr A Hamed, Amr Muhammed, Ebtsam A M Abdelbary, Ramy M Elsharkawy, Moustafa A Ali","doi":"10.1200/CCI.23.00216","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The standard practice for limited-stage hepatocellular carcinoma (HCC) is the resection or the use of local ablative techniques, such as radiofrequency ablation (RFA). The outcome after RFA depends on a complex interaction between the patient's general condition, hepatic function, and disease stage. In this study, we aimed to explore using a machine learning model to predict the response.</p><p><strong>Patients and methods: </strong>A retrospective study was conducted for patients with RFA for a localized HCC between 2018 and 2022. The collected clinical, radiologic, and laboratory data were explored using Python and XGBoost. They were split into a training set (70%) and a validation set (30%). The primary end point of this study was to predict the probability of achieving favorable outcomes 12 months after RFA. Favorable outcomes were defined as the patient was alive and HCC was controlled.</p><p><strong>Results: </strong>One hundred and eleven patients were eligible for the study. Males were 78 (70.3%) with a median age of 57 (range of 43-81) years. Favorable outcome was seen in 62 (55.9%) of the patients. The 1-year survival rate and control rate were 94.6%, and 61.3%, respectively. The final model harbored an accuracy and an AUC of 90.6% and 0.95, respectively, for the training set, while they were 78.9% and 0.80, respectively, for the validation set.</p><p><strong>Conclusion: </strong>Machine learning can be a predictive tool for the outcome after RFA in patients with HCC. Further validation by a larger study is necessary.</p>","PeriodicalId":51626,"journal":{"name":"JCO Clinical Cancer Informatics","volume":"8 ","pages":"e2300216"},"PeriodicalIF":3.3000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO Clinical Cancer Informatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/CCI.23.00216","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: The standard practice for limited-stage hepatocellular carcinoma (HCC) is the resection or the use of local ablative techniques, such as radiofrequency ablation (RFA). The outcome after RFA depends on a complex interaction between the patient's general condition, hepatic function, and disease stage. In this study, we aimed to explore using a machine learning model to predict the response.

Patients and methods: A retrospective study was conducted for patients with RFA for a localized HCC between 2018 and 2022. The collected clinical, radiologic, and laboratory data were explored using Python and XGBoost. They were split into a training set (70%) and a validation set (30%). The primary end point of this study was to predict the probability of achieving favorable outcomes 12 months after RFA. Favorable outcomes were defined as the patient was alive and HCC was controlled.

Results: One hundred and eleven patients were eligible for the study. Males were 78 (70.3%) with a median age of 57 (range of 43-81) years. Favorable outcome was seen in 62 (55.9%) of the patients. The 1-year survival rate and control rate were 94.6%, and 61.3%, respectively. The final model harbored an accuracy and an AUC of 90.6% and 0.95, respectively, for the training set, while they were 78.9% and 0.80, respectively, for the validation set.

Conclusion: Machine learning can be a predictive tool for the outcome after RFA in patients with HCC. Further validation by a larger study is necessary.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
机器学习能否预测肝细胞癌射频消融术后的有利结果?
目的:局限期肝细胞癌(HCC)的标准治疗方法是切除或使用局部消融技术,如射频消融(RFA)。射频消融术后的疗效取决于患者的一般状况、肝功能和疾病分期之间复杂的相互作用。在这项研究中,我们旨在探索使用机器学习模型来预测反应:我们对 2018 年至 2022 年期间因局部 HCC 而接受 RFA 治疗的患者进行了一项回顾性研究。我们使用 Python 和 XGBoost 对收集到的临床、放射学和实验室数据进行了探索。这些数据被分成训练集(70%)和验证集(30%)。本研究的主要终点是预测 RFA 12 个月后取得良好疗效的概率。有利结果的定义是患者存活且 HCC 得到控制:111名患者符合研究条件。其中男性 78 人(70.3%),中位年龄为 57 岁(43-81 岁不等)。62例(55.9%)患者的治疗效果良好。1年生存率和控制率分别为94.6%和61.3%。最终模型在训练集上的准确率和AUC分别为90.6%和0.95,而在验证集上的准确率和AUC分别为78.9%和0.80:结论:机器学习可以作为预测HCC患者RFA术后疗效的工具。结论:机器学习可以作为预测 HCC 患者 RFA 术后疗效的工具,有必要通过更大规模的研究进行进一步验证。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.20
自引率
4.80%
发文量
190
期刊最新文献
Development, Validation, and Clinical Utility of Electronic Patient-Reported Outcome Measure-Enhanced Prediction Models for Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy. Metastatic Versus Localized Disease as Inclusion Criteria That Can Be Automatically Extracted From Randomized Controlled Trials Using Natural Language Processing. Identifying Oncology Patients at High Risk for Potentially Preventable Emergency Department Visits Using a Novel Definition. Use of Patient-Reported Outcomes in Risk Prediction Model Development to Support Cancer Care Delivery: A Scoping Review. Optimizing End Points for Phase III Cancer Trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1